NITD-916

• Description :

  NITD-916, a 4-hydroxy-2-pyridone derivative, is an orally active mycobacterial enoyl reductase InhA inhibitor with an IC50 of 570 nM. NITD-916 forms a ternary complex with InhA and NADH to block access to the fatty acyl substrate binding pocket. NITD-916 inhibition of InhA reduces the synthesis of mycolic acids and results in cell death. NITD-916 has potent anti-tuberculosis effects[1][2].

• UNSPSC :

  12352005

• Target :

  Bacterial

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/nitd-916.html

• Purity :

  99.83

• Solubility :

  DMSO : 17.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C1C(C2=CC=CC=C2)=C(O)C=C(CC3CCC(C)(C)CC3)N1

• Molecular Formula :

  C20H25NO2

• Molecular Weight :

  311.42

• References & Citations :

  [1]Ujjini H Manjunatha, et al. Direct inhibitors of InhA are active against Mycobacterium tuberculosis. Sci Transl Med. 2015 Jan 7;7 (269) :269ra3.|[2]Matthew B McNeil, et al. Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA. Tuberculosis (Edinb) . 2017 Dec;107:133-136.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1614262-83-7]